Literature DB >> 24895231

Molecular mechanism of cholangiocarcinoma carcinogenesis.

Kosei Maemura1, Shoji Natsugoe, Sonshin Takao.   

Abstract

Cholangiocarcinoma (CCA) is a highly malignant cancer of the biliary tract with a poor prognosis, which often arises from conditions causing long-term inflammation, injury, and reparative biliary epithelial cell proliferation. Several conditions are known to be major risk factors for cancer in the biliary tract or gallbladder, including primary sclerosing cholangitis, liver fluke infection, pancreaticobiliary maljunction, and chemical exposure in proof-printing workers. Abnormalities in various signaling cascades, molecules, and genetic mutations are involved in the pathogenesis of CCA. CCA is characterized by a series of highly recurrent mutations in genes, including KRAS, BRF, TP53, Smad, and p16(INK4a) . Cytokines that are affected by inflammatory environmental conditions, such as interleukin-6 (IL-6), transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), and platelet-derived growth factor (PDGF), play an important role in cancer pathogenesis. Prominent signaling pathways important in carcinogenesis include TGF-β/Smad, IL-6/STAT-3, PI3K/AKT, Wnt, RAF/MEK/MAPK, and Notch. Additionally, some microRNAs regulate targets in critical pathways of CCA development and progression. This review article provides the understanding of the genetic and epigenetic mechanism(s) of carcinogenesis in CCA, which leads to the development of new therapeutic targets for the prevention and treatment of this devastating cancer.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Carcinogenesis; Cholangiocarcinoma; Signal transduction; microRNAs

Mesh:

Substances:

Year:  2014        PMID: 24895231     DOI: 10.1002/jhbp.126

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  25 in total

1.  MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma.

Authors:  Adrian P Mansini; Maria J Lorenzo Pisarello; Kristen M Thelen; Maetzin Cruz-Reyes; Estanislao Peixoto; Sujeong Jin; Brynn N Howard; Christy E Trussoni; Gabriella B Gajdos; Nicholas F LaRusso; Maria J Perugorria; Jesus M Banales; Sergio A Gradilone
Journal:  Hepatology       Date:  2018-05-21       Impact factor: 17.425

2.  Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis.

Authors:  L Yang; S Feng; Y Yang
Journal:  Cancer Gene Ther       Date:  2016-11-18       Impact factor: 5.987

Review 3.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201

4.  Antischistosomiasis Liver Fibrosis Effects of Chlorogenic Acid through IL-13/miR-21/Smad7 Signaling Interactions In Vivo and In Vitro.

Authors:  Yao Wang; Fan Yang; Jun Xue; Xuan Zhou; Lei Luo; Qian Ma; Yun-Fei Chen; Juan Zhang; Shu-Ling Zhang; Lei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Crosstalk between the Notch signaling pathway and non-coding RNAs in gastrointestinal cancers.

Authors:  Yangyang Pan; Yuyan Mao; Rong Jin; Lei Jiang
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

6.  Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Authors:  R S Finn; D H Ahn; M M Javle; B R Tan; C D Weekes; J C Bendell; A Patnaik; G N Khan; D Laheru; R Chavira; J Christy-Bittel; E Barrett; M B Sawyer; Tanios S Bekaii-Saab
Journal:  Invest New Drugs       Date:  2018-05-22       Impact factor: 3.850

7.  Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma.

Authors:  Qun-Xiong Pan; Zi-Jian Su; Jian-Hua Zhang; Chong-Ren Wang; Shao-Ying Ke
Journal:  Mol Clin Oncol       Date:  2017-02-16

8.  Repurposing cimetidine for cholangiocarcinoma: Antitumor effects in vitro and in vivo.

Authors:  Paweena Dana; Kulthida Vaeteewoottacharn; Ryusho Kariya; Kouki Matsuda; Sopit Wongkham; Seiji Okada
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

9.  MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7.

Authors:  Fei Fan; Jiongjiong Lu; Wenlong Yu; Yongjie Zhang; Suqian Xu; Leilei Pang; Bin Zhu
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

10.  HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma.

Authors:  Haixia Yang; Jiupeng Zhou; Jianqiang Mi; Ke Ma; Yangwei Fan; Jing Ning; Chuying Wang; Xin Wei; Huadong Zhao; Enxiao Li
Journal:  Oncol Rep       Date:  2015-08-10       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.